cdifflogoadjdtrdJoin us on November 8th and 9th, 2018 for the  6th Annual International C. diff. Awareness Conference and Health EXPO at the Embassy Suites by Hilton Philadelphia Airport, 9000 Bartram Avenue, Philadelphia, Pennsylvania, 19153, USA.  Registration Opens January 2018.  Clinical professionals will gather for two days to present up-to-date data to expand on the existing knowledge and raise awareness of the urgency focused on, yet not limited to,  a Clostridium difficile infection (CDI) –—Prevention, Treatments, Research, Environmental Safety, Clinical trials and studies focused on Microbiome research, Infection Prevention, Fecal Microbiota Restoration and Transplants.  There will be a Panel Of C. diff. Infection Survivors, Discussions about Probiotics, Antibiotic Stewardship, Presentations on Sepsis,  Nutrition and alterations in digestion, IBS-C and IBS-D, Diagnostics, Treatment, Healthcare EXPO ……………………and much more.

The audience will not want to miss out on the opportunity to learn from leading
International topic experts delivering data directed at evidence-based
prevention, treatments, and environmental safety in the C. diff.
and health care community.

  • SEE the difference.
  • LEARN more from the leading international topic-experts.
  • EXPERIENCE the outstanding intellectual minds and the many ways we can tap into the present and future healthcare components.
  • CONNECT with Corporate Sponsors and Exhibitors providing products and services focused on C. difficile and additional healthcare-associated Infections (HAI’s) worldwide.


Clostridium difficile is gram-positive, anaerobic, and a spore, rod/spindle-shape,
a common bacterium of the human intestine
in 2 – 5%. C diff. becomes a serious gastrointestinal infection when individuals have been exposed to antibiotic therapy, and/or have experienced a long-term hospitalization, and/or have had an extended stay in a long-term care facility. However; the risk of acquiring a C diff. infection (CDI) has increased as it is in the community and found in outpatient settings. There are significant risk factors in patients who are immunosuppressant, individuals who have been on antibiotic therapy, and the elderly population.

How do Antibiotics cause C diff.?  The antibiotics cause a disruption in the normal intestinal flora which leads to an over growth of C difficile bacteria in the colon. Leading antibiotics are known to disrupt the normal intestinal flora.

As far back as November 2012 the CDC started sharing a public announcement regarding antibiotic use: Colds and many ear and sinus infections are caused by viruses, not bacteria. Taking antibiotics to treat a “virus” can make those drugs less effective when you and your family really need them. Limiting the usage of antibiotics will also help limit new cases of CDI.
*Always discuss the symptoms and medications with the treating Physician/Healthcare Provider.

Contact Us Today —

Healthcare Providers, and Triage Nurses are available to speak with
Monday through Friday 9:00 a.m. ET – 5:00 p.m. ET with
limited on-call weekends, to learn more about C. diff.  Prevention,  Diagnosis   Symptoms and Transmission  Treatments, Environmental Safety and Support Worldwide.


U.S. Hot-Line  1-844-FOR-CDIF
(1-844-367-2343)  (Sponsored by Mr & Mrs R. Dunham)

U.S. Main Number: (919) – 201-1512


Previous studies indicate that C. difficile has become the most common microbial cause of healthcare-associated infections in U.S. hospitals and costs up to $4.8 billion each year in excess health care costs for acute care facilities alone.  The new study found that 1 out of every 5 patients with a healthcare-associated C. difficile infection experienced a recurrence of the infection and 1 out of every 9 patients aged 65 or older with a healthcare-associated
C. difficile infection died within 30 days of diagnosis.** (1)

The epidemiology of C. diff. infections in the UK:
The height of the epidemic of C. diff. infections in the UK was towards the end of the last decade.  There are comprehensive UK data on CDI because of a mandatory reporting system that was introduced over 10 years ago; in England there were ~60 000 cases in 2007-08, with large, hospital based outbreaks, some of which led to multiple official reviews of healthcare practice.  Major government-led public health campaigns followed, which included the use of targets for every NHS hospital, financial penalties if targets were missed, and (in 2012) standardized testing for CDI across the NHS.  These interventions led to an 80% reduction in CDI rates and in CDI associated mortality; in England there
were ~14 000 cases in 2013-14.  There was a small rise in CDI’s  (~6% in 2014-15), which is unexplained.  CDI remains a key performance management condition in the NHS, and so low rates are considered as a marker of high quality healthcare. (2)

There is validation enough for the C Diff Foundation to continue its’ dedication in lowering morbidity and mortality rates through continued education, advocating, and sharing the  C Diff Foundation mission in raising C. diff. awareness with healthcare professionals, healthcare students, healthcare facilities, patients, families, and communities – working towards a shared goal ~  To witness a reduction of newly diagnosed  C. diff. cases on a global level — by 2020.

The C Diff Foundation works closely within the healthcare industry, from villages to cities in thirty-eight countries with patients, and in many industries addressing the problems and discussing solutions focused on C. difficile, a common healthcare-associated infection (HAI).  “International Raising C.diff. Awareness” takes place through Summits, Symposiums, Workshops, and Annual Conferences each year. The first annual “International Raising C Diff Awareness” Conference was held in November 2013 and brought together some of the best minds in epidemiology and healthcare with new ideas regarding the challenges the world is facing in C.diff. prevention, treatments, and environmental safety. By and through presenting specific, scientific data to meet C. diff. challenges, encouraging healthcare professionals, healthcare organizations, and pharmaceutical organizations to share the
information and providing scientific data being utilized to implement C. diff.  solutions.

“Our Foundation is without borders as our outreach expands over horizons dedicated in our mission; Educating and advocating for C. difficile infection prevention, treatments, support, and environmental safety worldwide to end the suffering from this infection and help save lives.” states
Nancy C. Caralla, Foundress, Executive Director


None of us can do this alone…..all of us can do this together!”



NOVEMBER has been proclaimed  “C. difficile Awareness”  Month

JOIN US and Share Our Mission To Save Lives Worldwide!






*Please Read Disclaimer      Thank you. *

* If you are, or you know someone who is, experiencing
symptoms of a C. difficile infection, please contact a Physician and seek medical
attention immediately.


(1) http://www.cdc.gov/media/releases/2015/p0225-clostridium-difficile.html 

 (2) Dr. Mark Wilcox, MD, FRCPath, Consultant Microbiologist, Head of Microbiology and Academic Lead of Pathology at the Leeds Teaching Hospitals (LTHT), Professor of Medical Microbiology at the University of Leeds at their Institute of Biomedical and Clinical Sciences, and is the lead on Clostridium difficile for Public Health England in the UK, C Diff Foundation: Chairperson, Medical Advisory Board.

SIGN UP for C Diff Foundation 365 Monthly Newsletter